Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

Mutation analysis of therapy-related myeloid neoplasms.

Nishiyama T, Ishikawa Y, Kawashima N, Akashi A, Adachi Y, Hattori H, Ushijima Y, Kiyoi H.

Cancer Genet. 2018 Apr;222-223:38-45. doi: 10.1016/j.cancergen.2018.02.006. Epub 2018 Mar 8.

PMID:
29666007
2.

Introduction of Genetically-Modified CD3ΞΆ Improves Proliferation and Persistence of Antigen-specific CTLs.

Miyao K, Terakura S, Okuno S, Julamanee J, Watanabe K, Hamana H, Kishi H, Sakemura R, Koyama D, Goto T, Nishida T, Murata M, Kiyoi H.

Cancer Immunol Res. 2018 Apr 13. pii: canimm.0538.2017. doi: 10.1158/2326-6066.CIR-17-0538. [Epub ahead of print]

PMID:
29653982
3.

[MonoMAC syndrome patient developing myelodysplastic syndrome following persistent EBV infection].

Yamamoto H, Hattori H, Takagi E, Morishita T, Ishikawa Y, Terakura S, Nishida T, Ito Y, Murata M, Kiyoi H.

Rinsho Ketsueki. 2018;59(3):315-322. doi: 10.11406/rinketsu.59.315. Japanese.

PMID:
29618691
4.

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.

Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, Takagi H, Hagiwara D, Ito Y, Morishita Y, Goto M, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Arima H.

J Endocr Soc. 2018 Feb 6;2(3):241-251. doi: 10.1210/js.2017-00432. eCollection 2018 Mar 1.

5.

Analysis of the oligomeric states of nucleophosmin using size exclusion chromatography.

Sakashita G, Kiyoi H, Naoe T, Urano T.

Sci Rep. 2018 Mar 5;8(1):4008. doi: 10.1038/s41598-018-22359-w.

6.

Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200.

Harada K, Doki N, Miyazaki Y, Wakita A, Ohtake S, Takada S, Komatsu H, Kubo K, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Naoe T, Ohashi K.

Ann Hematol. 2018 Mar 1. doi: 10.1007/s00277-018-3281-1. [Epub ahead of print] No abstract available.

PMID:
29497807
7.

Efficacy and safety of autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: A study protocol for a multicenter exploratory prospective study (Auto-Ph17 study).

Nishiwaki S, Sugiura I, Miyata Y, Saito S, Sawa M, Nishida T, Miyamura K, Kuwatsuka Y, Kohno A, Yuge M, Kasai M, Iida H, Kurahashi S, Osaki M, Goto T, Terakura S, Murata M, Nishikawa H, Kiyoi H.

Medicine (Baltimore). 2017 Dec;96(52):e9568. doi: 10.1097/MD.0000000000009568.

8.

Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.

Harada Y, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Onizuka M, Takeshita A, Ishida F, Suzushima H, Ishizawa K, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group JALSG.

Leuk Res. 2018 Mar;66:20-27. doi: 10.1016/j.leukres.2018.01.008. Epub 2018 Jan 17.

PMID:
29360622
9.

Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia.

Kamijo R, Itonaga H, Kihara R, Nagata Y, Hata T, Asou N, Ohtake S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T, Kiyoi H, Miyazaki Y.

Leuk Res. 2018 Feb;65:34-41. doi: 10.1016/j.leukres.2017.12.006. Epub 2018 Jan 2.

PMID:
29306105
10.

Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.

Harada K, Doki N, Hagino T, Miyawaki S, Ohtake S, Kiyoi H, Miyazaki Y, Fujita H, Usui N, Okumura H, Miyamura K, Nakaseko C, Fujieda A, Nagai T, Yamane T, Sakamaki H, Ohnishi K, Naoe T, Ohno R, Ohashi K.

Ann Hematol. 2018 Jan;97(1):73-81. doi: 10.1007/s00277-017-3156-x. Epub 2017 Dec 2.

PMID:
29196987
11.

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.

Yamaura T, Nakatani T, Uda K, Ogura H, Shin W, Kurokawa N, Saito K, Fujikawa N, Date T, Takasaki M, Terada D, Hirai A, Akashi A, Chen F, Adachi Y, Ishikawa Y, Hayakawa F, Hagiwara S, Naoe T, Kiyoi H.

Blood. 2018 Jan 25;131(4):426-438. doi: 10.1182/blood-2017-05-786657. Epub 2017 Nov 29.

PMID:
29187377
12.

Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.

Shirahata-Adachi M, Iriyama C, Tomita A, Suzuki Y, Shimada K, Kiyoi H.

Leuk Res. 2017 Dec;63:90-97. doi: 10.1016/j.leukres.2017.10.015. Epub 2017 Nov 4.

PMID:
29127861
13.

Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia.

Adachi Y, Ishikawa Y, Kiyoi H.

Oncotarget. 2017 Jul 26;8(45):78452-78465. doi: 10.18632/oncotarget.19632. eCollection 2017 Oct 3.

14.

Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.

Kuwatsuka Y, Tomizawa D, Kihara R, Nagata Y, Shiba N, Iijima-Yamashita Y, Shimada A, Deguchi T, Miyachi H, Tawa A, Taga T, Kinoshita A, Nakayama H, Kiyokawa N, Saito AM, Koh K, Goto H, Kosaka Y, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Ogawa S, Naoe T, Hayashi Y, Horibe K, Manabe A, Mizutani S, Adachi S, Kiyoi H.

Int J Hematol. 2018 Feb;107(2):201-210. doi: 10.1007/s12185-017-2340-z. Epub 2017 Oct 12.

PMID:
29027108
15.

High incidence of extensive chronic graft-versus-host disease in patients with the REG3A rs7588571 non-GG genotype.

Koyama D, Murata M, Hanajiri R, Okuno S, Kamoshita S, Julamanee J, Takagi E, Hirano D, Miyao K, Sakemura R, Goto T, Hayakawa F, Seto A, Ozawa Y, Miyamura K, Terakura S, Nishida T, Kiyoi H.

PLoS One. 2017 Sep 25;12(9):e0185213. doi: 10.1371/journal.pone.0185213. eCollection 2017.

16.

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, Miyata Y, Kobayashi S, Usuki K, Matsumura I, Minami Y, Usui N, Fukuda T, Takada S, Ishikawa M, Fujimaki K, Gomyo H, Sasaki O, Ohishi K, Miyake T, Imai K, Suzushima H, Mitsui H, Togitani K, Kiguchi T, Atsuta Y, Ohtake S, Ohnishi K, Kobayashi Y, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group.

Int J Hematol. 2018 Feb;107(2):185-193. doi: 10.1007/s12185-017-2334-x. Epub 2017 Sep 19.

PMID:
28929332
17.

High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG.

Sakura T, Hayakawa F, Sugiura I, Murayama T, Imai K, Usui N, Fujisawa S, Yamauchi T, Yujiri T, Kakihana K, Ito Y, Kanamori H, Ueda Y, Miyata Y, Kurokawa M, Asou N, Ohnishi K, Ohtake S, Kobayashi Y, Matsuo K, Kiyoi H, Miyazaki Y, Naoe T.

Leukemia. 2018 Mar;32(3):626-632. doi: 10.1038/leu.2017.283. Epub 2017 Sep 15.

PMID:
28914260
18.

A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).

Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M; for National Research Group on Idiopathic Bone Marrow Failure Syndromes.

Am J Hematol. 2017 Dec;92(12):1324-1332. doi: 10.1002/ajh.24905. Epub 2017 Sep 28.

PMID:
28891083
19.

Clinical effectiveness of geriatric assessment for predicting the tolerability of outpatient chemotherapy in older adults with cancer.

Hayashi N, Matsuoka A, Goto H, Gotoh M, Kiyoi H, Kodera Y, Nagino M, Nagashima F, Ando Y.

J Geriatr Oncol. 2018 Jan;9(1):84-86. doi: 10.1016/j.jgo.2017.07.014. Epub 2017 Aug 9. No abstract available.

PMID:
28802840
20.

Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group.

Kimura SI, Fujita H, Kato H, Hiramoto N, Hosono N, Takahashi T, Shigeno K, Hatsumi N, Minamiguchi H, Miyatake J, Handa H, Akiyama N, Kanda Y, Yoshida M, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group (JALSG).

Support Care Cancer. 2017 Nov;25(11):3515-3521. doi: 10.1007/s00520-017-3775-8. Epub 2017 Jun 6.

PMID:
28584934
21.

Phase II study of intrabone single unit cord blood transplantation for hematological malignancies.

Murata M, Maeda Y, Masuko M, Onishi Y, Endo T, Terakura S, Ishikawa Y, Iriyama C, Ushijima Y, Goto T, Fujii N, Tanimoto M, Kobayashi H, Shibasaki Y, Fukuhara N, Inamoto Y, Suzuki R, Kodera Y, Matsushita T, Kiyoi H, Naoe T, Nishida T.

Cancer Sci. 2017 Aug;108(8):1634-1639. doi: 10.1111/cas.13291. Epub 2017 Jun 29.

22.

[I.Genetic Abnormalities Associated with Acute Leukemia and a Development of Molecular Therapies].

Adachi Y, Kiyoi H.

Gan To Kagaku Ryoho. 2017 May;44(5):380-385. Japanese. No abstract available.

PMID:
28536332
23.

Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.

Togasaki E, Takeda J, Yoshida K, Shiozawa Y, Takeuchi M, Oshima M, Saraya A, Iwama A, Yokote K, Sakaida E, Hirase C, Takeshita A, Imai K, Okumura H, Morishita Y, Usui N, Takahashi N, Fujisawa S, Shiraishi Y, Chiba K, Tanaka H, Kiyoi H, Ohnishi K, Ohtake S, Asou N, Kobayashi Y, Miyazaki Y, Miyano S, Ogawa S, Matsumura I, Nakaseko C, Naoe T.

Blood Cancer J. 2017 Apr 28;7(4):e559. doi: 10.1038/bcj.2017.36.

24.

YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma.

Kojima Y, Hayakawa F, Morishita T, Sugimoto K, Minamikawa Y, Iwase M, Yamamoto H, Hirano D, Imoto N, Shimada K, Okada S, Kiyoi H.

Pharmacol Res. 2017 Jun;120:242-251. doi: 10.1016/j.phrs.2017.04.006. Epub 2017 Apr 8.

PMID:
28396094
25.

Malignant lymphoma with cardiac involvement.

Terakura S, Onji M, Iriyama C, Goto T, Ushijima Y, Shimada K, Ishikawa Y, Nishida T, Hayakawa F, Murata M, Kiyoi H.

Rinsho Ketsueki. 2017;58(3):239-242. doi: 10.11406/rinketsu.58.239. Japanese.

PMID:
28381692
26.

Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study.

Yokohata E, Kuwatsuka Y, Ohashi H, Terakura S, Kawashima N, Seto A, Kurahashi S, Ozawa Y, Goto T, Imahashi N, Nishida T, Miyao K, Sakemura R, Kato T, Sawa M, Kohno A, Sao H, Iida H, Kiyoi H, Naoe T, Miyamura K, Murata M.

Bone Marrow Transplant. 2017 Apr;52(4):612-614. doi: 10.1038/bmt.2016.323. Epub 2017 Jan 9. No abstract available.

PMID:
28067879
27.

Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism.

Aoki T, Shimada K, Sakamoto A, Sugimoto K, Morishita T, Kojima Y, Shimada S, Kato S, Iriyama C, Kuno S, Harada Y, Tomita A, Hayakawa F, Kiyoi H.

Oncotarget. 2017 Feb 21;8(8):13085-13098. doi: 10.18632/oncotarget.14393.

28.

Corrigendum: Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.

Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H.

Nat Genet. 2016 Nov 29;48(12):1591. doi: 10.1038/ng1216-1587a. No abstract available.

PMID:
27898077
29.

Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms.

Mori T, Nagata Y, Makishima H, Sanada M, Shiozawa Y, Kon A, Yoshizato T, Sato-Otsubo A, Kataoka K, Shiraishi Y, Chiba K, Tanaka H, Ishiyama K, Miyawaki S, Mori H, Nakamaki T, Kihara R, Kiyoi H, Koeffler HP, Shih LY, Miyano S, Naoe T, Haferlach C, Kern W, Haferlach T, Ogawa S, Yoshida K.

Leukemia. 2016 Nov;30(11):2270-2273. doi: 10.1038/leu.2016.212. Epub 2016 Aug 1. No abstract available.

PMID:
27479181
30.

Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells.

Fukushima N, Minami Y, Kakiuchi S, Kuwatsuka Y, Hayakawa F, Jamieson C, Kiyoi H, Naoe T.

Cancer Sci. 2016 Oct;107(10):1422-1429. doi: 10.1111/cas.13019. Epub 2016 Sep 2.

31.

Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device.

Matsuoka A, Mitsuma A, Maeda O, Kajiyama H, Kiyoi H, Kodera Y, Nagino M, Goto H, Ando Y.

Cancer Sci. 2016 Oct;107(10):1453-1457. doi: 10.1111/cas.13010. Epub 2016 Sep 2.

32.

Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study.

Suzuki N, Hirakawa A, Kishimoto M, Kanematsu T, Ogawa M, Kiyoi H, Matsushita T.

Haemophilia. 2017 Mar;23(2):215-221. doi: 10.1111/hae.13082. Epub 2016 Oct 5.

PMID:
27704637
33.

Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.

Goto T, Nishida T, Takagi E, Miyao K, Koyama D, Sakemura R, Hanajiri R, Watanabe K, Imahashi N, Terakura S, Murata M, Kiyoi H.

J Immunother. 2016 Oct;39(8):306-15. doi: 10.1097/CJI.0000000000000136.

PMID:
27548033
34.

The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib.

Morishita T, Hayakawa F, Sugimoto K, Iwase M, Yamamoto H, Hirano D, Kojima Y, Imoto N, Naoe T, Kiyoi H.

Oncotarget. 2016 Aug 30;7(35):56241-56252. doi: 10.18632/oncotarget.11025.

35.

SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway.

Takagi Y, Shimada K, Shimada S, Sakamoto A, Naoe T, Nakamura S, Hayakawa F, Tomita A, Kiyoi H.

Cancer Sci. 2016 Sep;107(9):1270-80. doi: 10.1111/cas.13001. Epub 2016 Sep 6.

36.

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells.

Chen F, Ishikawa Y, Akashi A, Naoe T, Kiyoi H.

Oncotarget. 2016 Jul 26;7(30):47018-47032. doi: 10.18632/oncotarget.10147.

37.

A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.

Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K, Koyama D, Goto T, Hanajiri R, Nishida T, Murata M, Kiyoi H.

Cancer Immunol Res. 2016 Aug;4(8):658-68. doi: 10.1158/2326-6066.CIR-16-0043. Epub 2016 Jun 21.

38.

Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes.

Suzuki Y, Tomita A, Nakamura F, Iriyama C, Shirahata-Adachi M, Shimada K, Akashi A, Ishikawa Y, Kaneda N, Kiyoi H.

Cancer Sci. 2016 Sep;107(9):1329-37. doi: 10.1111/cas.12994. Epub 2016 Aug 25.

39.

Live-cell single-molecule imaging of the cytokine receptor MPL for analysis of dynamic dimerization.

Sakamoto A, Tsukamoto T, Furutani Y, Sudo Y, Shimada K, Tomita A, Kiyoi H, Kato T, Funatsu T.

J Mol Cell Biol. 2016 Dec;8(6):553-555. Epub 2016 Jun 9. No abstract available.

PMID:
27282404
40.

PAX5 tyrosine phosphorylation by SYK co-operatively functions with its serine phosphorylation to cancel the PAX5-dependent repression of BLIMP1: A mechanism for antigen-triggered plasma cell differentiation.

Inagaki Y, Hayakawa F, Hirano D, Kojima Y, Morishita T, Yasuda T, Naoe T, Kiyoi H.

Biochem Biophys Res Commun. 2016 Jun 24;475(2):176-81. doi: 10.1016/j.bbrc.2016.05.067. Epub 2016 May 13.

PMID:
27181361
41.

BCR-ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells.

Ueda N, Zhang R, Tatsumi M, Liu TY, Kitayama S, Yasui Y, Sugai S, Iwama T, Senju S, Okada S, Nakatsura T, Kuzushima K, Kiyoi H, Naoe T, Kaneko S, Uemura Y.

Cell Mol Immunol. 2018 Jan;15(1):15-26. doi: 10.1038/cmi.2016.7. Epub 2016 May 15.

PMID:
27181332
42.

Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.

Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H.

Nat Genet. 2016 May;48(5):569-74. doi: 10.1038/ng.3535. Epub 2016 Mar 28. Erratum in: Nat Genet. 2016 Nov 29;48(12 ):1591.

PMID:
27019113
43.

Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma.

Shimada K, Shimada S, Sugimoto K, Nakatochi M, Suguro M, Hirakawa A, Hocking TD, Takeuchi I, Tokunaga T, Takagi Y, Sakamoto A, Aoki T, Naoe T, Nakamura S, Hayakawa F, Seto M, Tomita A, Kiyoi H.

Leukemia. 2016 Jul;30(7):1568-79. doi: 10.1038/leu.2016.67. Epub 2016 Mar 22.

PMID:
27001523
44.

Identification of Meflin as a Potential Marker for Mesenchymal Stromal Cells.

Maeda K, Enomoto A, Hara A, Asai N, Kobayashi T, Horinouchi A, Maruyama S, Ishikawa Y, Nishiyama T, Kiyoi H, Kato T, Ando K, Weng L, Mii S, Asai M, Mizutani Y, Watanabe O, Hirooka Y, Goto H, Takahashi M.

Sci Rep. 2016 Feb 29;6:22288. doi: 10.1038/srep22288.

45.

B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.

Imoto N, Hayakawa F, Kurahashi S, Morishita T, Kojima Y, Yasuda T, Sugimoto K, Tsuzuki S, Naoe T, Kiyoi H.

J Biol Chem. 2016 Feb 26;291(9):4723-31. doi: 10.1074/jbc.M115.637835. Epub 2015 Dec 24.

46.

High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma.

Aoki T, Shimada K, Suzuki R, Izutsu K, Tomita A, Maeda Y, Takizawa J, Mitani K, Igarashi T, Sakai K, Miyazaki K, Mihara K, Ohmachi K, Nakamura N, Takasaki H, Kiyoi H, Nakamura S, Kinoshita T, Ogura M.

Blood Cancer J. 2015 Dec 4;5:e372. doi: 10.1038/bcj.2015.101. No abstract available.

47.

[The Cutting-edge of Medicine; Genetic alterations and their prognostic implications in acute myeloid leukemia].

Kiyoi H.

Nihon Naika Gakkai Zasshi. 2015 Jun 10;104(6):1180-8. Japanese. No abstract available.

PMID:
26571766
48.

Overview: A New Era of Cancer Genome in Myeloid Malignancies.

Kiyoi H.

Oncology. 2015;89 Suppl 1:1-3. doi: 10.1159/000431054. Epub 2015 Nov 10. Review.

PMID:
26551625
49.

[Necessity of Genetic Examination in Treatment for Hematological Malignancies].

Kiyoi H.

Rinsho Byori. 2015 Mar;63(3):369-76. Review. Japanese.

PMID:
26524860
50.

Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood.

Kitamura K, Nishiyama T, Ishiyama K, Miyawaki S, Miyazaki K, Suzuki K, Masaie H, Okada M, Ogawa H, Imai K, Kiyoi H, Naoe T, Yokoyama Y, Chiba S, Hata T, Miyazaki Y, Hatta Y, Takeuchi J, Nannya Y, Kurokawa M, Ueda Y, Koga D, Sugiyama H, Takaku F.

Int J Hematol. 2016 Jan;103(1):53-62. doi: 10.1007/s12185-015-1882-1. Epub 2015 Oct 31.

PMID:
26520650

Supplemental Content

Support Center